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Summary 
Background: High-flow nasal cannulae (HFNC) create positive oropharyngeal airway pressure but it 
is unclear how their use affects lung volume. Electrical impedance tomography (EIT) allows 
assessment of changes in lung volume by measuring changes in lung impedance. Primary objectives 
were to investigate the effects of HFNC on airway pressure (Paw) and end-expiratory lung volume 
(EELV), and to identify any correlation between the two. Secondary objectives were to investigate the 
effects of HFNC on respiratory rate (RR), dyspnoea, tidal volume and oxygenation; and the interaction 
between body mass index (BMI) and EELV. 
Methods: Twenty patients prescribed HFNC post-cardiac surgery were investigated. Impedance 
measures, Paw, PaO2/FiO2 ratio, RR and modified Borg scores were recorded first on low flow oxygen 
(nasal cannula or Hudson face mask) and then on HFNC. 
Results: A strong and significant correlation existed between Paw and end-expiratory lung impedance 
(EELI) (r=0.7, p<0.001). Compared with low flow oxygen, HFNC significantly increased EELI by 25.6% 
(95% CI 24.3, 26.9) and Paw by 3.0 cmH2O (95% CI 2.4, 3.7). RR reduced by 3.4 breaths per minute 
(95% CI 1.7, 5.2) with HFNC use, tidal impedance variation increased by 10.5% (95% CI 6.1, 18.3) 
and PaO2/FiO2 ratio improved by 30.6 mmHg (95% CI 17.9, 43.3). HFNC improved subjective 
dyspnoea scoring (p=0.023). Increases in EELI were significantly influenced by BMI, with larger 
increases associated with higher BMIs (p<0.001). 
Conclusions: This study suggests that HFNC improve dyspnoea and oxygenation by increasing both 
EELV and tidal volume, and are most beneficial in patients with higher BMIs. 
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Introduction 
Pulmonary complications post cardiac surgery are common 1 and are associated with adverse 
outcomes, including prolonged mechanical ventilation times, increased use of sedation, increased risk 
of ventilator-associated pneumonia, and prolonged Intensive Care Unit (ICU) and hospital lengths of 
stay 2 3. Alveolar collapse and atelectasis is observed in up to 90% of post surgical cases 4 and 
subsequently results in a reduction in functional residual capacity (FRC) of approximately 20% 1. 
Physiotherapy and early mobilisation may provide some benefit, but respiratory dysfunction is still 
commonplace 5. Non-invasive ventilation can be useful in avoiding reintubation in such patients, but 
this treatment prevents early mobilisation; is associated with gastric distension which may further 
reduce FRC; restricts effective communication and oral nutrition; and is poorly tolerated in some 
patients 6.  
 
High-flow nasal cannulae (HFNC) deliver high flow humidified air and oxygen via wide bore 
nasal cannulae at a prescribed fraction of inspired oxygen (FiO2). Whereas conventional nasal prongs 
are generally limited to flows of 5 litre min-1 due to the potential drying effects of cold oxygen on the 
nasal mucosa 7, oxygen at up to 50 litre min-1 may be delivered when the warmed gas is optimally 
humidified, making it less irritant to the nasal mucosal. The therapy is well established in neonatal and 
paediatric populations 8 9 and HFNC use has recently been described in adult populations 10 11. 
 
A number of studies have described the generation of positive airway pressure at the level of 
the pharynx associated with HFNC 12-14. However, there is no data regarding the translation of this 
pharyngeal positive pressure effect to the lungs, nor any data describing associated changes in lung 
volumes. This is essential in understanding if HFNC provide any clinically relevant benefit. 
 
Electrical impedance tomography (EIT) is a non-invasive radiation-free bedside imaging technique 
used to provide real-time images and data of regional lung ventilation and lung volumes (Figure 1) 15. 
Its use has been validated in a number of clinical applications including optimisation of mechanical 
ventilatory strategies such as lung recruitment manoeuvres 16; detection of pulmonary complications 
including lung collapse, pleural effusion and pneumothorax 17 18; and ensuring correct placement of the 
endotracheal tube 19. EIT allows the effects of HFNC on lung volumes to be accurately assessed.  
 4
 
The primary aims of this prospective interventional study were to compare the differences in 
airway pressure (Paw) and end-expiratory lung volume (EELV) between HFNC and low flow oxygen, 
and to determine any relationship between changes in Paw and EELV. Secondary aims were to 
investigate the changes in respiratory rate (RR), subjective rating of dyspnoea (modified Borg score), 
tidal volume (Vt), and oxygenation (PaO2/FiO2 ratio) between the two therapies. Due to the association 
between increased body mass index and decreased in FRC in the post-operative period 20, we 
assessed the interaction between BMI and changes in EELV in patients on HFNC. 
 
Methods 
Following approval from the Institutional Human Research and Ethics Committee (EC27105), 
this study was conducted at a tertiary referral hospital in Australia specialising in cardiothoracic 
surgery and medicine. The study was registered with the Australian Clinical Trials Registry (Clinical 
Trial No: ACTRN12609000037202). 
 
Participants 
Written informed consent was obtained from all participants. Patients were included in the 
study if they were deemed by the treating intensive care specialist to be displaying signs of respiratory 
dysfunction (including one or more of decreasing PaO2 [PaO2/FiO2 ratio of < 300], subjective 
dyspnoea, increased use of accessory muscles, increase in respiratory rate) and requiring HFNC; 
post-cardiac surgery (on cardio-pulmonary bypass); and ≥ 18 years of age. Patients were excluded if 
they had ongoing air leak post-surgery, a requirement for electrical cardiac pacing or an open 
sternum. 
 
Electrical Impedance Tomography 
Lung volume changes were assessed using EIT. Previous studies have demonstrated that 
changes in end-expiratory lung impedance (EELI) as measured by EIT have a strong linear correlation 
with changes in EELV 21 22. Similarly, Vt changes are correlated with tidal impedance variation (VARt) 
22. Therefore the effect of HFNC at a pulmonary, rather than an oropharyngeal airway level, can be 
accurately assessed. 
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EIT measurements were performed with the EIT Evaluation Kit 2 (Dräger Medical, Lübeck, 
Germany) which had been calibrated and self-tested according to manufacturer’s instructions. EIT files 
were automatically saved to the device’s hard drive, analysed by the Dräger review software V5.1 and 
then downloaded as a Microsoft™ Excel spreadsheet.  
 
Study protocol 
Patients were assessed in an upright position either in bed (at a head of bed elevation of at 
least 45 degrees as measured by an angle measurement device) or sitting in a straight backed chair. 
Pain levels were assessed, and analgesia administered if necessary, to ensure patients could breathe 
without discomfort and restriction. After instillation of Co-phenylcaine Forte Nasal spray into the nares, 
an eight French feeding tube (Unomedical, Sydney, Australia) was inserted nasally to the level of the 
oropharynx. Correct placement was confirmed both by visual inspection and capnography (Marquette 
monitor, GE Medical Systems Information Technologies Inc., Wisconsin, USA). The tube was then 
connected to a precision pressure transducer (PPT-001, DWWW2V, Honeywell international Ltd, 
Minneapolis, USA) to measure Paw and the data downloaded directly to a Microsoft™ Excel 
spreadsheet. Figure 2 shows a representative example of the airway pressure tracing obtained. 
 
An appropriately-sized electrode belt was placed around the circumference of the patient’s 
chest, at the level of the anterior intercostal space 5–6, and an optimal EIT signal was confirmed prior 
to data collection. For female patients, the placement of the belt was standardised to underneath the 
breast tissue. Data were collected first on low flow oxygen, then on HFNC. The order of data collection 
was unable to be randomised as the participants were requiring HFNC as part of their treatment. Prior 
to the measurement of the low flow oxygen data, patients were asked to rate their dyspnoea level 
using the Modified Borg Dyspnoea Scale 23 and asked to keep their mouth closed if possible during 
the measurement period. The patient’s mouth status (open or closed) was tracked every 30 seconds 
during the measurement period. Simultaneous 2 minute Paw, EELI and VARt readings were then 
recorded while the patient was receiving oxygen therapy via a low flow system (either nasal cannula or 
Hudson face mask) at the flow rate the patient was receiving prior to HFNC prescription. FiO2 on low 
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flow was estimated using a previously described standardised algorithm 24. An arterial blood gas 
(ABG) was taken at this time in all patients if an intra-arterial line (IAL) was in situ.  
 
HFNC (Optiflow™ system, MR850 heated humidified, RT202 delivery tubing & RT050/051 
nasal cannulae, Fisher and Paykel Healthcare Ltd, Auckland, New Zealand) were applied with the 
humidifier temperature set to 37C to optimise humidification. The FiO2 was titrated to patient need to 
maintain SpO2 levels ≥ 95% and flow was commenced at 35 litre min-1. This flow rate was titrated 
upwards to a maximum of 50 litre min-1 as determined by patient tolerance, as is the clinical practice in 
the unit. A 15 minute washout period was used between therapies to counter any cumulative 
treatment effect. The patient was again asked to score their dyspnoea whilst reminded to keep their 
mouth closed if possible. After optimal signals were confirmed on both the EIT and pressure 
transducer, simultaneous 2 minute EIT and Paw measurements were repeated in addition to an ABG.  
 
Supplementary data included patient demographics, including height and weight to assess 
BMI. Data analysed from the EIT files were EELI, VARt and RR. Mean Paw was measured in cm H2O 
from the pressure transducer files. 
 
Initially, the investigators chose to exclude patients requiring cardiac pacing as there was no 
safety data regarding the interaction between EIT and cardiac pacing. After consultation with 
colleagues who routinely use EIT to study post cardiac surgical neonates with temporary epicardial 
pacing, it was found that in a 12 month period, no adverse events occurred. Therefore, late in the 
study, this exclusion criterion was removed. Only one patient was recruited using the amended 
exclusion criteria. 
 
Statistical Analysis 
To investigate the changes in lung volumes (EELI and VARt) for the EIT data, a mixed effects 
regression model was used. A mixed model extends a standard regression model by allowing 
repeated results from the same individual which we modelled using a random intercept. The 
dependent variable was EIT and the independent variable was HFNC (yes/no). Spearman’s 
correlation coefficient was used to determine any correlation between EELI and Paw change. A second 
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independent variable of mouth closed (yes/no) was added to test its effect on EELI. An interaction 
term was included to examine if the effectiveness of the HFNC depended on BMI. To investigate 
changes Vt, RR, modified Borg score and PaO2/FiO2 ratio, a paired t-test was used. Any p values less 
than 0.05/6=0.008 were considered significant after making a Bonferroni adjustment for multiple 
comparisons. Data was assessed using an intention to treat analysis. All analyses were performed 
using the R statistical software (www.r-project.org). 
 
Results 
Twenty seven patients were eligible for inclusion into the study and were approached for 
informed consent. Two patients refused insertion of the nasopharyngeal catheter, two patients 
required epicardial pacing to be commenced just prior to the study period, one male patient could not 
be fitted with a correctly-sized EIT belt due to their chest circumference and the EIT was unable to 
pass the manufacturer’s self test in a further two patients. Therefore, twenty patients who were 
prescribed HFNC by the intensive care specialist post-cardiac surgery were recruited, 15 of whom 
were male.  The mean (and range) age of participants was 65.3 (51–77) years; height was 171.1 
(160–183); weight was 93.3 (60–123); and BMI was 32 (22–45) kg m-2. Selected clinical parameters of 
participants are shown in Table 1. Two patients were unable to provide complete data due to the 
absence of an IAL in one patient and the inability to tolerate the nasopharyngeal catheter in the other. 
Using an intention to treat analysis, data from these two patients was included. 
 
When compared with a low flow oxygen device, HFNC increased mean Paw by 3.0 cm H2O 
(95% CI 2.4, 3.7; paired t-test p<0.001) and EELI by 1517 impedance units (95% CI 1425, 1608; 
mixed model p<0.001). This translates to an increase in EELI of 25.6% (95% CI 24.3, 26.9; mixed 
model p<0.001) on HFNC, suggesting a similar increase in EELV. No statistically significant difference 
was found in EELI when the patients’ mouth was closed or open (mixed model p=0.99). No significant 
correlation was found between Paw and mouth open or closed (p=0.99). A strong and significant 
correlation was found between Paw and EELI (r=0.7, p<0.001). RR was lowered by 3.4 breaths per 
minute (95% CI 1.7, 5.2; paired t-test p<0.001) and the Borg dyspnoea score by 0.8 points (95% CI 
0.1, 1.4; paired t-test p=0.023). HFNC significantly increased VARt by 159 impedance units (95% CI 
117, 202; mixed model p<0.001), translating to a 10.5% increase (95%CI 6.1, 18.3; mixed model 
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p<0.001). This finding suggests a similar increase in Vt. PaO2/FiO2 ratio was improved by 30.6 (95% 
CI 17.9, 43.3; paired t-test p<0.001) even though 95% of patients were receiving an equal or lower 
FiO2 while on HFNC than when on low flow oxygen. Table 2 summarises the primary and secondary 
outcome measures.  
 
Higher gas flow rates were found to result in larger increases in EELI. For every one L/min 
increase in flow rate, the difference in EELI between low flow oxygen device and HFNC increases by a 
further 0.7% (95% CI 0.1, 1.3; mixed model p-value=0.023).  
 
BMI significantly influenced the positive effect of HFNC on EELI (mixed model p<0.001). A 
BMI of 25 resulted in a mean increase in EELI of 13.3% (high versus low flow) whereas with a BMI of 
40 the increase was 24.4%. Figure 3 shows the mean increases in EELI (expressed as a percentage 
increase) by BMI.  
 
Discussion 
This data indicates for the first time that HFNC are associated with an increase in EELI in 
patients post cardiac surgery, suggesting an increase in EELV and hence FRC. The increase in EELV 
was found to be significantly greater in those subjects with a higher BMI. The generation of positive 
oropharyngeal Paw by HFNC reported in earlier studies 12-14 was confirmed. In addition, significant 
decreases were recorded in RR and the patients’ perceived dyspnoea, and significant increases were 
recorded in Vt and oxygenation. The benefits of positive airway pressure and the resultant increase in 
EELV include a reduction in work of breathing, prevention of small airway closure, and improved 
oxygenation due to reduced pulmonary shunting 25. This increase in EELV, coupled with the reduction 
in RR and the patients’ perceived dyspnoea, could mean that HFNC use in post cardiac surgical 
patients may be of substantial clinical benefit in the patient with borderline respiratory function post 
extubation. 
 
HFNC have been shown to generate between 0.2 and 4.8 cm H2O of positive Paw in neonatal 
and paediatric populations 26 27. In healthy adult volunteers, HFNC generated between 5.1 and 8.7 cm 
H2O pharyngeal Paw 12 14. The findings of our study are similar to the only other published work 
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investigating the effects of HFNC on Paw in adult intensive care patients 13. We found no significant 
correlation between Paw and mouth open or closed (p=0.99) in this study, which is at odds with 
previous studies 12 14.  
 
EELI was found to increase with the transition from low to high flow oxygen delivery in 90% of 
the participants in this study. Due to the strong linear relationship between changes in EELI and EELV 
demonstrated in previous EIT studies 21 22, it can therefore be concluded that the use of HFNC 
increases EELV. This increase in EELV may be explained by the recruitment of alveoli, and prevention 
of further alveolar collapse, as a result of the low level positive Paw generated by HFNC. Additionally, 
the increase could be attributed to further expansion of partially recruited alveoli. 
 
With a mean BMI of 32 m−2 kg in the study cohort, the increase in EELV was significantly 
greater in those patients with higher BMI (Figure 3). Obese patients are predisposed to post-operative 
atelectasis and this atelectasis resolves more slowly than in patients with normal body weight (38). 
Additionally, this group of patients is prone to reduced FRC with an increased risk of developing 
further respiratory complications 29. Therefore it appears that patients with higher BMIs may derive 
particular benefit from the low level positive airway pressure and increase in EELV that HFNC 
produce. This may be explained by the pre-existing derangement in respiratory mechanics displayed 
in obese patients, specifically the higher closing volumes and subsequent reduction in lung volume 
due to excessive unopposed intra-abdominal pressure 30. Subsequently, the obese patient will have a 
higher number of recruitable alveoli than a patient with a normal BMI and this may account for the 
beneficial effects seen in the obese group. More work in this area is required to further explore and 
describe the interaction observed between EELV and BMI, particularly as more than one third of 
patients undergoing cardiac surgery at this institution have a BMI ≥ 30. 
 
A statistically significant reduction in RR was observed on HFNC. While no formal 
measurements of work of breathing were employed, the mean drop in RR of 3.4 breaths per minute 
may result in a reduction in work of breathing 31. An improvement in lung compliance and FRC could 
be significant factors in the improvement in subjective dyspnoea, and may also be partially responsible 
for the observed decrease in RR.  
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A higher PaO2/FiO2 ratio was demonstrated in patients using HFNC. This could be attributed 
in part to the observed increase in EELV and resultant increase in alveolar ventilation. However, the 
PaO2/FiO2 ratio would also be improved by the use of higher inspired oxygen concentration, as is seen 
in high flow oxygen devices. Interestingly, 95% of patients in this study were receiving an equal or 
lower FiO2 while on HFNC than when on low flow oxygen, with 50% receiving a lower FiO2 while on 
HFNC. 
 
Gas flow rates, which determine inspired oxygen concentration particularly at lower flows, 
were not standardised across patients in this study. Instead, a clinically driven protocol was chosen 
which reflected clinical practice and management of these patients and clinical usage of the device. 
The assessment of the effects of HFNC at different flow rates may be of interest in future studies to 
further delineate optimal flows. 
 
Whilst the sample size of this study was small, the investigators were able to describe 
significant differences in clinical markers between low flow oxygen and HFNC usage in a typical post 
cardiac surgical cohort. A larger sample size will be necessary to investigate the effects of HFNC on 
longer term outcomes. Our cohort consisted of more males than females at a ratio of 3:1, which is 
reflective of global trends in cardiac surgery 32.  
 
This study confirms that HFNC are effective in providing modest levels of positive airway 
pressure and, for the first time, clearly demonstrates that this translates to increases in EELV. These 
increases in lung volume, and the associated improvements in RR, subjective dyspnoea and 
oxygenation, necessitate further investigation if the clinical significance of HFNC usage and its impact 
on patients’ longer term outcomes is to be established. These questions will be addressed in a 
subsequent randomised controlled trial which will examine the effects of HFNC on postoperative 
atelectasis in patients with a BMI ≥ 30 (Australian Clinical Trials Registry, Clinical Trial No: 
ACTRN12610000942055). 
 
Conclusions 
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HFNC generate statistically and clinically relevant increases in oropharyngeal airway 
pressure, and increases in end expiratory lung volume and tidal volume as demonstrated by changes 
in lung impedance, particularly in patients with higher BMIs. These changes are associated with 
reduced respiratory rate, less dyspnoea and improved oxygenation. Thus, HFNC may be a useful 
treatment option for patients experiencing respiratory dysfunction post-cardiac surgery, particularly 
those patients who cannot tolerate non-invasive ventilation and those with a higher BMI.  
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